← Back to search results

AwardedFind a Tender · award

Reagents and Bioinformatics analysis

Buyer: NHS Grampian →

BuyerNHS Grampian
StatusAwarded
DeadlineNot published
ValueValue not published
Published4 Jun 2024

What is being bought

Next Generation Sequencing (NGS) kits

Delivery location

UKM50

Categories

Laboratory reagents 33696500Laboratory reagents 33696500

Lot details

Lot 1

Award value estimated based on previous spend for 2023-24 financial year. This is a direct award to the existing supplier to save a significant amount of rework that would be required if the genetics lab was to switch to an alternative supplier. This will cover the spend for 2024-25 financial year. It is vital that the supply of these items is uninterrupted as any delay will impact on patient care including cancer surgery / treatments, stem cell transplants for patients with primary immune deficiencies and bone marrow failure and correct patient management to prevent irreversible brain damage in metabolic conditions.

Statuscancelled

Award criteria
price

What is included

ItemCategoryQuantity
1Laboratory reagentsNot published

Comparable-procurement analytics

Benchmarked against retained Find a Tender procedures with CPV division 33. The category anchor is Laboratory reagents (33696500); this is a deliberately broad market comparator. The comparison is shown at several levels rather than pretending one company or region is always the best benchmark.

Comparison setProceduresReported bids per procedureNamed award suppliersPrice evidence
Market: CPV division 334,8542 median · 122.5 average (2,277 of 4,854 with a bid count)5.8 average (2,723 of 4,854 with named award suppliers)Not published
Same buyer171 median · 1.5 average (13 of 17 with a bid count)1 average (13 of 17 with named award suppliers)Not published
Delivery region: UKM50311 median · 2.8 average (24 of 31 with a bid count)2 average (24 of 31 with named award suppliers)Not published

“Reported bids” is an official aggregate, sometimes reported per lot; it is the closest available competition measure. “Named award suppliers” are winners, not all applicants.

Price-outcome signal

Not enough comparable procedures currently publish both a GBP tender value and a usable lowest-valid-bid value to calculate a responsible price-reduction benchmark. Tenderline deliberately does not infer a saving from named award suppliers or from missing award values.

Procurement strategy & market signals

Framework agreementNot published
Dynamic purchasing systemNot published
Competitive procurementNot published
Recurring requirementNot published
Procurement method rationaleWe have a number of services within the department that use Next Generation Sequencing (NGS) kits supplied by SOPHiA Genetics. These services are funded by National Services division (NSD) and the Aberdeen laboratory provides National services for Hereditary Breast, Ovarian and prostate cancer, Cardiac arrhythmias and Whole exome sequencing (for metabolic, gastrohepatology, chromosome breakage / inherited bone marrow failure and eye disorders) using these SOPHiA kits. These are essential established reagents used in these testing pathways, having previously undergone extensive validation processes within the laboratory. Purchase of alternative reagents would involve delay to testing as additional extensive validation work would need to be undertaken before use. An integral bioinformatics solution, SOPHiA DDM, is included in the price of these SOPHiA kits which provides cost-effective, streamlined analysis for these patient samples. In addition, SOPHiA DDM is used to analyse NGS data for other rare and inherited conditions using tailored analysis pipelines. This includes Primary Immune Deficiencies, Familial Hypercholesterolaemia and tumour testing for metastatic prostate cancer. This is charged on a cost per sample upload basis and allows clinical scientists to analyse the data in an efficient manner without the need for specialist bioinformaticians. Purchase of bioinformatics services from another provider would take a significant amount of time for the validation work required to ensure accurate results are obtained and would incur significant costs for extensive validation. Furthermore, additional staff would be required to perform the bioinformatics processes that would be required in the absence of the SOPHiA DDM platform for all of the national genetics services mentioned above. It is vital that the supply of these items is uninterrupted as any delay will impact on patient care including cancer surgery / treatments, stem cell transplants for patients with
Rationale classificationsThe works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons
Special regimeNot published
Covered byNot published
Submission policyNot published
Selection criteriaNot published
Risk detailsNot published

Planning & early market engagement

BudgetNot published
No-engagement rationaleNot published
Planning documents0
Planning milestones0

No planning milestones published.

Related procurements

No linked framework, prior procurement or reprocurement published.

Awards

Contracts

017321-2024-NC006-24-1

Statusactive
Value£352,000

Documents & submission route

No documents are published in the current source record.

Source data inventory

Diagnostic view. “Not published” means this current release does not provide a value.

OCIDocds-h6vhtk-046d5a
Latest release ID017321-2024
Latest release timestampTue Jun 04 2024 15:02:45 GMT+0000 (Coordinated Universal Time)
Sourcefind-a-tender
Official notice URLNot published
Tender statuscomplete
Procurement methodlimited
Procurement method detailsAward procedure without prior publication of a call for competition
Main procurement categorygoods
Above thresholdNot published
Legal basis32014L0024
Tender period: startNot published
Tender period: endNot published
Expression of interest deadlineNot published
Enquiry deadlineNot published
Award period: startNot published
Award period: endNot published
Submission method detailsNot published
Submission languagesNot published
Electronic catalogue policyNot published
Total tender valueNot published
Tender lots in source1
Tender items in source1
Tender documents in source0
Awards in latest release1
Contracts in latest release1
Parties in latest release3

Notice history

DateEventReference
4 Jun 2024award, contract017321-2024

All source data

Unmodified official OCDS data retained by Tenderline for this procurement process.

Complete current OCDS release JSON
{
  "id": "017321-2024",
  "tag": [
    "award",
    "contract"
  ],
  "bids": {
    "statistics": [
      {
        "id": "1",
        "value": 1,
        "measure": "bids",
        "relatedLot": "1"
      },
      {
        "id": "2",
        "value": 0,
        "measure": "smeBids",
        "relatedLot": "1"
      },
      {
        "id": "3",
        "value": 0,
        "measure": "foreignBidsFromEU",
        "relatedLot": "1"
      },
      {
        "id": "4",
        "value": 1,
        "measure": "foreignBidsFromNonEU",
        "relatedLot": "1"
      },
      {
        "id": "5",
        "value": 1,
        "measure": "electronicBids",
        "relatedLot": "1"
      }
    ]
  },
  "date": "2024-06-04T16:02:45+01:00",
  "ocid": "ocds-h6vhtk-046d5a",
  "buyer": {
    "id": "GB-FTS-4312",
    "name": "NHS Grampian"
  },
  "links": [
    {
      "rel": "canonical",
      "href": "https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000767636"
    }
  ],
  "awards": [
    {
      "id": "017321-2024-NC006-24-1",
      "status": "active",
      "suppliers": [
        {
          "id": "GB-FTS-115208",
          "name": "SOPHiA GENETICS Ltd"
        }
      ],
      "relatedLots": [
        "1"
      ]
    }
  ],
  "tender": {
    "id": "NC006-24",
    "lots": [
      {
        "id": "1",
        "status": "cancelled",
        "hasOptions": false,
        "description": "Award value estimated based on previous spend for 2023-24 financial year.\nThis is a direct award to the existing supplier to save a significant amount of rework that would be required if the genetics lab was to switch to an alternative supplier.\nThis will cover the spend for 2024-25 financial year.\nIt is vital that the supply of these items is uninterrupted as any delay will impact on patient care including cancer surgery / treatments, stem cell transplants for patients with primary immune deficiencies and bone marrow failure and correct patient management to prevent irreversible brain damage in metabolic conditions.",
        "awardCriteria": {
          "criteria": [
            {
              "type": "price"
            }
          ]
        }
      }
    ],
    "items": [
      {
        "id": "1",
        "relatedLot": "1",
        "deliveryLocation": {
          "description": "Aberdeen Royal Infirmary"
        },
        "deliveryAddresses": [
          {
            "region": "UKM50"
          }
        ],
        "additionalClassifications": [
          {
            "id": "33696500",
            "scheme": "CPV",
            "description": "Laboratory reagents"
          }
        ]
      }
    ],
    "title": "Reagents and Bioinformatics analysis",
    "status": "complete",
    "legalBasis": {
      "id": "32014L0024",
      "scheme": "CELEX"
    },
    "description": "Next Generation Sequencing (NGS) kits",
    "classification": {
      "id": "33696500",
      "scheme": "CPV",
      "description": "Laboratory reagents"
    },
    "procurementMethod": "limited",
    "mainProcurementCategory": "goods",
    "procurementMethodDetails": "Award procedure without prior publication of a call for competition",
    "procurementMethodRationale": "We have a number of services within the department that use Next Generation Sequencing (NGS) kits supplied by SOPHiA Genetics. These services are funded by National Services division (NSD) and the Aberdeen laboratory provides National services for Hereditary Breast, Ovarian and prostate cancer, Cardiac arrhythmias and Whole exome sequencing (for metabolic, gastrohepatology, chromosome breakage / inherited bone marrow failure and eye disorders) using these SOPHiA kits. These are essential established reagents used in these testing pathways, having previously undergone extensive validation processes within the laboratory. Purchase of alternative reagents would involve delay to testing as additional extensive validation work would need to be undertaken before use. An integral bioinformatics solution, SOPHiA DDM, is included in the price of these SOPHiA kits which provides cost-effective, streamlined analysis for these patient samples. In addition, SOPHiA DDM is used to analyse NGS data for other rare and inherited conditions using tailored analysis pipelines. This includes Primary Immune Deficiencies, Familial Hypercholesterolaemia and tumour testing for metastatic prostate cancer. This is charged on a cost per sample upload basis and allows clinical scientists to analyse the data in an efficient manner without the need for specialist bioinformaticians. Purchase of bioinformatics services from another provider would take a significant amount of time for the validation work required to ensure accurate results are obtained and would incur significant costs for extensive validation. Furthermore, additional staff would be required to perform the bioinformatics processes that would be required in the absence of the SOPHiA DDM platform for all of the national genetics services mentioned above. It is vital that the supply of these items is uninterrupted as any delay will impact on patient care including cancer surgery / treatments, stem cell transplants for patients with",
    "procurementMethodRationaleClassifications": [
      {
        "id": "D_TECHNICAL",
        "scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
        "description": "The works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons"
      }
    ]
  },
  "parties": [
    {
      "id": "GB-FTS-4312",
      "name": "NHS Grampian",
      "roles": [
        "buyer"
      ],
      "address": {
        "region": "UKM50",
        "locality": "Aberdeen",
        "postalCode": "AB15 6RE",
        "countryName": "United Kingdom",
        "streetAddress": "Summerfield House, 2 Eday Road"
      },
      "details": {
        "url": "http://www.nhsgrampian.org",
        "buyerProfile": "https://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA00200",
        "classifications": [
          {
            "id": "BODY_PUBLIC",
            "scheme": "TED_CA_TYPE",
            "description": "Body governed by public law"
          },
          {
            "id": "07",
            "scheme": "COFOG",
            "description": "Health"
          }
        ]
      },
      "identifier": {
        "legalName": "NHS Grampian"
      },
      "contactPoint": {
        "email": "simon.ogg@nhs.scot",
        "telephone": "+44 3454566000"
      }
    },
    {
      "id": "GB-FTS-115208",
      "name": "SOPHiA GENETICS Ltd",
      "roles": [
        "supplier"
      ],
      "address": {
        "region": "UK",
        "locality": "London",
        "postalCode": "SW19 2RR",
        "countryName": "United Kingdom",
        "streetAddress": "60 Windsor Avenue"
      },
      "details": {
        "scale": "large"
      },
      "identifier": {
        "legalName": "SOPHiA GENETICS Ltd"
      },
      "contactPoint": {
        "telephone": "+44 7395594261"
      }
    },
    {
      "id": "GB-FTS-114651",
      "name": "Aberdeen Sheriff Court and Justice of Peace Court",
      "roles": [
        "reviewBody"
      ],
      "address": {
        "locality": "Aberdeen",
        "countryName": "United Kingdom"
      },
      "identifier": {
        "legalName": "Aberdeen Sheriff Court and Justice of Peace Court"
      }
    }
  ],
  "language": "en",
  "contracts": [
    {
      "id": "017321-2024-NC006-24-1",
      "value": {
        "amount": 352000,
        "currency": "GBP"
      },
      "status": "active",
      "awardID": "017321-2024-NC006-24-1",
      "dateSigned": "2024-05-24T00:00:00+01:00"
    }
  ],
  "description": "(SC Ref:767636)",
  "initiationType": "tender"
}
Complete JSON history (1 releases)
4 Jun 2024 · 017321-2024 · award, contract
{
  "id": "017321-2024",
  "tag": [
    "award",
    "contract"
  ],
  "bids": {
    "statistics": [
      {
        "id": "1",
        "value": 1,
        "measure": "bids",
        "relatedLot": "1"
      },
      {
        "id": "2",
        "value": 0,
        "measure": "smeBids",
        "relatedLot": "1"
      },
      {
        "id": "3",
        "value": 0,
        "measure": "foreignBidsFromEU",
        "relatedLot": "1"
      },
      {
        "id": "4",
        "value": 1,
        "measure": "foreignBidsFromNonEU",
        "relatedLot": "1"
      },
      {
        "id": "5",
        "value": 1,
        "measure": "electronicBids",
        "relatedLot": "1"
      }
    ]
  },
  "date": "2024-06-04T16:02:45+01:00",
  "ocid": "ocds-h6vhtk-046d5a",
  "buyer": {
    "id": "GB-FTS-4312",
    "name": "NHS Grampian"
  },
  "links": [
    {
      "rel": "canonical",
      "href": "https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000767636"
    }
  ],
  "awards": [
    {
      "id": "017321-2024-NC006-24-1",
      "status": "active",
      "suppliers": [
        {
          "id": "GB-FTS-115208",
          "name": "SOPHiA GENETICS Ltd"
        }
      ],
      "relatedLots": [
        "1"
      ]
    }
  ],
  "tender": {
    "id": "NC006-24",
    "lots": [
      {
        "id": "1",
        "status": "cancelled",
        "hasOptions": false,
        "description": "Award value estimated based on previous spend for 2023-24 financial year.\nThis is a direct award to the existing supplier to save a significant amount of rework that would be required if the genetics lab was to switch to an alternative supplier.\nThis will cover the spend for 2024-25 financial year.\nIt is vital that the supply of these items is uninterrupted as any delay will impact on patient care including cancer surgery / treatments, stem cell transplants for patients with primary immune deficiencies and bone marrow failure and correct patient management to prevent irreversible brain damage in metabolic conditions.",
        "awardCriteria": {
          "criteria": [
            {
              "type": "price"
            }
          ]
        }
      }
    ],
    "items": [
      {
        "id": "1",
        "relatedLot": "1",
        "deliveryLocation": {
          "description": "Aberdeen Royal Infirmary"
        },
        "deliveryAddresses": [
          {
            "region": "UKM50"
          }
        ],
        "additionalClassifications": [
          {
            "id": "33696500",
            "scheme": "CPV",
            "description": "Laboratory reagents"
          }
        ]
      }
    ],
    "title": "Reagents and Bioinformatics analysis",
    "status": "complete",
    "legalBasis": {
      "id": "32014L0024",
      "scheme": "CELEX"
    },
    "description": "Next Generation Sequencing (NGS) kits",
    "classification": {
      "id": "33696500",
      "scheme": "CPV",
      "description": "Laboratory reagents"
    },
    "procurementMethod": "limited",
    "mainProcurementCategory": "goods",
    "procurementMethodDetails": "Award procedure without prior publication of a call for competition",
    "procurementMethodRationale": "We have a number of services within the department that use Next Generation Sequencing (NGS) kits supplied by SOPHiA Genetics. These services are funded by National Services division (NSD) and the Aberdeen laboratory provides National services for Hereditary Breast, Ovarian and prostate cancer, Cardiac arrhythmias and Whole exome sequencing (for metabolic, gastrohepatology, chromosome breakage / inherited bone marrow failure and eye disorders) using these SOPHiA kits. These are essential established reagents used in these testing pathways, having previously undergone extensive validation processes within the laboratory. Purchase of alternative reagents would involve delay to testing as additional extensive validation work would need to be undertaken before use. An integral bioinformatics solution, SOPHiA DDM, is included in the price of these SOPHiA kits which provides cost-effective, streamlined analysis for these patient samples. In addition, SOPHiA DDM is used to analyse NGS data for other rare and inherited conditions using tailored analysis pipelines. This includes Primary Immune Deficiencies, Familial Hypercholesterolaemia and tumour testing for metastatic prostate cancer. This is charged on a cost per sample upload basis and allows clinical scientists to analyse the data in an efficient manner without the need for specialist bioinformaticians. Purchase of bioinformatics services from another provider would take a significant amount of time for the validation work required to ensure accurate results are obtained and would incur significant costs for extensive validation. Furthermore, additional staff would be required to perform the bioinformatics processes that would be required in the absence of the SOPHiA DDM platform for all of the national genetics services mentioned above. It is vital that the supply of these items is uninterrupted as any delay will impact on patient care including cancer surgery / treatments, stem cell transplants for patients with",
    "procurementMethodRationaleClassifications": [
      {
        "id": "D_TECHNICAL",
        "scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
        "description": "The works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons"
      }
    ]
  },
  "parties": [
    {
      "id": "GB-FTS-4312",
      "name": "NHS Grampian",
      "roles": [
        "buyer"
      ],
      "address": {
        "region": "UKM50",
        "locality": "Aberdeen",
        "postalCode": "AB15 6RE",
        "countryName": "United Kingdom",
        "streetAddress": "Summerfield House, 2 Eday Road"
      },
      "details": {
        "url": "http://www.nhsgrampian.org",
        "buyerProfile": "https://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA00200",
        "classifications": [
          {
            "id": "BODY_PUBLIC",
            "scheme": "TED_CA_TYPE",
            "description": "Body governed by public law"
          },
          {
            "id": "07",
            "scheme": "COFOG",
            "description": "Health"
          }
        ]
      },
      "identifier": {
        "legalName": "NHS Grampian"
      },
      "contactPoint": {
        "email": "simon.ogg@nhs.scot",
        "telephone": "+44 3454566000"
      }
    },
    {
      "id": "GB-FTS-115208",
      "name": "SOPHiA GENETICS Ltd",
      "roles": [
        "supplier"
      ],
      "address": {
        "region": "UK",
        "locality": "London",
        "postalCode": "SW19 2RR",
        "countryName": "United Kingdom",
        "streetAddress": "60 Windsor Avenue"
      },
      "details": {
        "scale": "large"
      },
      "identifier": {
        "legalName": "SOPHiA GENETICS Ltd"
      },
      "contactPoint": {
        "telephone": "+44 7395594261"
      }
    },
    {
      "id": "GB-FTS-114651",
      "name": "Aberdeen Sheriff Court and Justice of Peace Court",
      "roles": [
        "reviewBody"
      ],
      "address": {
        "locality": "Aberdeen",
        "countryName": "United Kingdom"
      },
      "identifier": {
        "legalName": "Aberdeen Sheriff Court and Justice of Peace Court"
      }
    }
  ],
  "language": "en",
  "contracts": [
    {
      "id": "017321-2024-NC006-24-1",
      "value": {
        "amount": 352000,
        "currency": "GBP"
      },
      "status": "active",
      "awardID": "017321-2024-NC006-24-1",
      "dateSigned": "2024-05-24T00:00:00+01:00"
    }
  ],
  "description": "(SC Ref:767636)",
  "initiationType": "tender"
}